Your browser doesn't support javascript.
loading
Use of a Scalable Replicon-Particle Vaccine to Protect Against Lethal Lassa Virus Infection in the Guinea Pig Model.
Kainulainen, Markus H; Spengler, Jessica R; Welch, Stephen R; Coleman-McCray, JoAnn D; Harmon, Jessica R; Klena, John D; Nichol, Stuart T; Albariño, César G; Spiropoulou, Christina F.
Afiliación
  • Kainulainen MH; Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Spengler JR; Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Welch SR; Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Coleman-McCray JD; Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Harmon JR; Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Klena JD; Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Nichol ST; Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Albariño CG; Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Spiropoulou CF; Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia.
J Infect Dis ; 217(12): 1957-1966, 2018 05 25.
Article en En | MEDLINE | ID: mdl-29800368
Lassa fever is a viral zoonosis that can be transmitted from person to person, especially in the hospital setting. The disease is endemic to several countries in West Africa and can be a major contributor to morbidity and mortality in affected areas. There are no approved vaccines to prevent Lassa virus infection. In this work, we present a vaccine candidate that combines the scalability and efficacy benefits of a live vaccine with the safety benefits of single-cycle replication. The system consists of Lassa virus replicon particles devoid of the virus essential glycoprotein gene, and a cell line that expresses the glycoprotein products, enabling efficient vaccine propagation. Guinea pigs vaccinated with these particles showed no clinical reaction to the inoculum and were protected against fever, weight loss, and lethality after infection with Lassa virus.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Replicón / Vacunas Virales / Fiebre de Lassa / Virus Lassa Límite: Animals País/Región como asunto: Africa Idioma: En Revista: J Infect Dis Año: 2018 Tipo del documento: Article País de afiliación: Georgia

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Replicón / Vacunas Virales / Fiebre de Lassa / Virus Lassa Límite: Animals País/Región como asunto: Africa Idioma: En Revista: J Infect Dis Año: 2018 Tipo del documento: Article País de afiliación: Georgia